Polypeptide variants with altered effector function
The present invention concerns polypeptides comprising a variant Fc region. More particularly, the present invention concerns Fc region-containing polypeptides that have altered effector function as a consequence of one or more amino acid modifications in the Fc region thereof.
1. A variant of a parent polypeptide comprising an Fc region, wherein the Fc region mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in the presence of human effector cells more effectively, or binds an Fc gamma receptor (FcγR) with better affinity, than the parent polypeptide and wherein the Fc region comprises an amino acid modification at amino acid position 339 wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.
2. The variant of claim 1 which is an antibody.
3. The variant of claim 1 wherein the parent polypeptide Fc region comprises a human IgG Fc region.
4. The variant of claim 3 wherein the human IgG Fc region comprises a human IgG1, IgG2, IgG3 or IgG4 Fc region.
5. The variant of claim 1 which mediates ADCC about 1.5 fold to about 100 fold more effectively than the parent polypeptide.
6. The variant of claim 1 which binds an FcγRIII with better affinity than the parent polypeptide.
7. The variant of claim 6 which further binds an FcγRII with worse affinity than the parent polypeptide.
8. A composition comprising the variant of claim 1 and a pharmaceutically acceptable carrier.
9. The composition of claim 8 which is sterile.
10. The variant of claim 1 , wherein the amino acid modification is A339T.
11. A polypeptide comprising a variant Fc region which is not a native sequence Fc region, wherein the variant Fc region comprises an amino acid substitution at amino acid position 339 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.
12. The polypeptide of claim 11 wherein the variant Fc region mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in the presence of human effector cells more effectively than a native sequence Fc region.
13. The polypeptide of claim 11 , wherein the variant Fc region binds an Fc gamma receptor (FcγR) with better affinity than a native sequence Fc region.
14. The polypeptide of claim 11 , wherein the variant Fc region mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in the presence of human effector cells more effectively and which binds an Fc gamma receptor (FcγR) with better affinity than a native sequence Fc region.
15. The polypeptide of claim 13 , wherein the FcγR is FcγRIIIA.
16. The polypeptide of claim 11 , wherein the variant Fc region comprises a human IgG Fc region.
17. The polypeptide of claim 16 , wherein the variant Fc region comprises a variant human IgG1 Fc region or a variant human IgG3 Fc region.
18. The polypeptide of claim 17 , wherein the variant Fc region comprises a variant human IgG1 Fc region.
19. The polypeptide of claim 11 , wherein amino acid position 339 is substituted with Thr.
20. The polypeptide of claim 11 which is an antibody or an immunoadhesin.
21. The polypeptide of claim 20 is comprises an antibody.